My watch list  

5 Current news of Actelion

matching the following criteria

Management change at Actelion


Actelion Ltd announced that Roland Haefeli, Senior Vice President, Head of Investor Relations and Public Affairs (IR & PA) and member of the Extended Actelion Executive Committee (AEC) has decided to step down from his current role for personal reasons effective 05 May 2014. Roland Haefeli will ...


Actelion's ponesimod successful in mid-stage trial in patients with plaque psoriasis

Ponesimod to proceed to Phase III clinical development in psoriasis


Actelion announced that its selective S1P1 modulator, ponesimod, successfully met the primary endpoint - the proportion of patients with at least 75% improvement in Psoriasis Area and Severity Index (PASI) from baseline (PASI75) at week 16 - in a double blind, placebo-controlled study conducted ...


Positive study with Actelion's bosentan (Tracleer®) in CTEPH


Actelion Ltd announced the initial results from the double-blind, placebo-controlled, multicenter study BENEFiT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension). The study met its primary objective, as treatment with bosentan (Tracleer®) was associated with ...


Actelion and Roche enter into autoimmune disorder collaboration


Actelion Ltd and Roche have announced today that they have entered into an exclusive worldwide collaboration to jointly develop and commercialize Actelion's selective S1P1 receptor agonist, an immunomodulator with the potential for once-a-day oral dosing. The compound is currently being developed ...


Tracleer Excellence Post Marketing Surveillance Programme (TRAX PMSTM) confirms long-term safety profile


Actelion Ltd announced that two abstracts presented at the European Society of Cardiology (ESC) conference confirm the long-term safety profile of Tracleer® (bosentan) in treating pulmonary arterial hypertension (PAH). Both abstracts comprise data from TRAX PMSTM, which was set up in the EU in ...


Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE